Stock events for Ligand Pharmaceuticals, Inc. (LGND)
Ligand Pharmaceuticals' stock has experienced strong financial performance, reporting strong fourth-quarter and full-year 2025 results and raised guidance for 2026. The stock price has seen significant appreciation, exceeding the US Pharmaceuticals industry and the US Market. Analysts have largely maintained a bullish outlook, but Wall Street Zen downgraded Ligand Pharmaceuticals from a "buy" to a "hold" rating. CFO Octavio Espinoza sold 13,423 shares of the company's stock. Ligand hosted its 2025 Investor Day on December 9, 2025, where it presented robust financial expectations for 2026 and highlighted strong performance in 2025.
Demand Seasonality affecting Ligand Pharmaceuticals, Inc.’s stock price
Information regarding the specific demand seasonality for Ligand Pharmaceuticals' products and services is not explicitly detailed in the provided search results. Seasonality analysis for LGND's stock price indicates recurring patterns over a calendar year. Historically, June has shown the highest probability of positive returns for LGND stock, while May has the lowest probability. March also suggests a high probability of a positive return.
Overview of Ligand Pharmaceuticals, Inc.’s business
Ligand Pharmaceuticals, Inc. is an American biopharmaceutical company focused on acquiring and developing royalty-generating assets within the Healthcare sector. Its business model centers on drug discovery, early-stage drug development, product reformulation, and strategic partnerships, deriving revenue from royalties, license and milestone payments, and Captisol sales. Ligand's portfolio includes royalty rights to approximately 90 pharmaceutical products across various therapeutic areas, including Captisol, Multiple Myeloma Treatments, Kidney Disease Therapy, Pneumococcal Vaccines, Infectious Diseases, Oncology, Diabetes, Osteoporosis, Respiratory Disease and other therapeutic areas.
LGND’s Geographic footprint
Ligand Pharmaceuticals, Inc. is headquartered in Jupiter, Florida, and operates globally through alliances, licenses, and business relationships with pharmaceutical companies like Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.
LGND Corporate Image Assessment
Ligand Pharmaceuticals has maintained a generally positive brand reputation, driven by its strong financial performance and strategic business model. Consistent royalty growth, successful product launches, and positive analyst sentiment contribute to a favorable perception. Potential weaknesses and threats identified in a SWOT analysis, such as reliance on third-party collaborations, single supplier risks for Captisol, intense competition, and stringent regulatory landscapes, could indirectly pose risks to its reputation if not managed effectively.
Ownership
Ligand Pharmaceuticals Incorporated has significant institutional ownership, with 591 institutional owners holding a total of 26,192,948 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Janus Henderson Group Plc. Major individual/insider owners include Bvf Partners L P, David M. Knott, and Daniel S. Loeb. Institutional ownership accounts for approximately 90.35% of the company, with individuals holding about 2.61%.
